Core Viewpoint - The AI healthcare sector is experiencing significant growth, driven by partnerships and investments aimed at accelerating AI applications in pharmaceuticals and healthcare management [1] Group 1: Stock Performance - AI healthcare concept stocks have mostly risen, with notable increases: Ark Health (06086) up 30.8%, Medical Pulse (02192) up 5.1%, Crystal Technology (02228) up 4.63%, Alibaba Health (00241) up 3.14%, and iFlytek Medical Technology (02506) up 2.79% [1] Group 2: Major Developments - NVIDIA and Eli Lilly announced a $1 billion investment to establish a joint research lab in the San Francisco Bay Area over the next five years, aimed at accelerating AI applications in the pharmaceutical industry [1] - The lab will begin operations in early 2023, with engineers from NVIDIA collaborating with experts in biology, science, and medicine to generate large-scale data and build AI models for new drug development [1] Group 3: Industry Insights - According to Founder Securities, AI-driven healthcare is forming a new growth pole, with a positive outlook on the revolutionary potential of AI in pharmaceuticals, basic research, diagnostics, and health management [1] - Huafu Securities noted that the AI healthcare industry has entered a critical phase of commercialization, supported by national strategies and market demand, with a closed-loop demand for AI applications sustaining the sustainable development of the AI industry [1]
AI医疗概念股多数走高 方舟健客涨超30% 英伟达携手礼来斥资10亿美元联合建立实验室